AR072796A1 - VACCINE STABILIZER AND COMPOSITION THAT INCLUDES ONE OR MORE FLAVIVIRUS LIVED OR CHEMERIC. STABILIZATION METHOD KIT - Google Patents
VACCINE STABILIZER AND COMPOSITION THAT INCLUDES ONE OR MORE FLAVIVIRUS LIVED OR CHEMERIC. STABILIZATION METHOD KITInfo
- Publication number
- AR072796A1 AR072796A1 ARP090102524A ARP090102524A AR072796A1 AR 072796 A1 AR072796 A1 AR 072796A1 AR P090102524 A ARP090102524 A AR P090102524A AR P090102524 A ARP090102524 A AR P090102524A AR 072796 A1 AR072796 A1 AR 072796A1
- Authority
- AR
- Argentina
- Prior art keywords
- live attenuated
- stabilizer
- flaviviruses
- vaccine
- dehydrated
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 12
- 241000710831 Flavivirus Species 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 229940124974 vaccine stabilizer Drugs 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 abstract 8
- 229960005486 vaccine Drugs 0.000 abstract 7
- 239000003381 stabilizer Substances 0.000 abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 abstract 1
- -1 4- (2-hydroxyethyl) -1- piperazinyl Chemical group 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 239000007995 HEPES buffer Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 108010004073 cysteinylcysteine Proteins 0.000 abstract 1
- 229960003067 cystine Drugs 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229910000160 potassium phosphate Inorganic materials 0.000 abstract 1
- 235000011009 potassium phosphates Nutrition 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
- 150000004043 trisaccharides Chemical class 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Un estabilizador para composiciones de vacuna que comprende uno o más flavivirus vivos atenuados, que comprende, en una solucion acuosa sin proteínas de origen animal y sin sales agregadas que tiene: cationes divalentes; un buffer; 2,5% a 6,5% de sorbitol; 2,5% a 13% de sucrosa; 0 a 7,5% de trehalosa y/o 0 a 7,5% de cualquier otro disacárido o trisacárido; 0,2% a 0,5% de urea; 0,8% a 2,5% de una mezcla de aminoácido que comprende arginina (Arg), cistina (Cys-Cys), histidina (His), isoleucina (Ile), leucina (Leu), lisina (Lys), metionina (Met), fenilalanina (Phe), teonina (Thr), triptofano (Trp), tirosina (Tyr), valina (Val), alanina (Ala), asparagina (Asn), ácido aspártico (Asp), ácido glutámico (Glu), glicina (Gly), prolina (Pro) y serina (Ser). Reivindicacion 2: El estabilizador de acuerdo con la reivindicacion 1, que comprende uno o más buffers seleccionados entre el grupo integrado por TRIS (tris(hidroximetil)-aminometano), HEPES ácido (2-(4-(2-hidroxietil)-1-piperazinil)etano-sulfonico) y fosfato de potasio y/o fosfato de sodio. Reivindicacion 6: Una composicion de vacuna acuosa a granel estabilizada que comprende uno o más flavivirus vivos atenuados y el estabilizador segun se reivindica en una o más de las reivindicaciones 1 a 5. Reivindicacion 15: Un método para estabilizar uno o más flavivirus vivos atenuados, que comprende la dilucion de una coleccion viral purificada y concentrada que comprende uno o más flavivirus vivos atenuados mediante el agregado de estabilizador de modo de obtener las concentraciones finales del estabilizador que se definieron de acuerdo con las reivindicaciones 1 a 5 a fin de obtener una composicion de acuerdo a lo que se reivindica en una o más de las reivindicaciones 6 a 14. Reivindicacion 22: Una composicion de vacuna deshidratada que se obtuvo mediante el secado de la composicion a granel estabilizada segun se reivindica en uno o más de las reivindicaciones 6 a 14. Reivindicacion 23: La composicion de vacuna deshidrata de acuerdo con la reivindicacion 22, que se encuentra presente en la forma de partículas uniformes o de esferas. Reivindicacion 24: La composicion de vacuna deshidratada de acuerdo con la reivindicacion 23, donde cada partícula o cada esfera contiene una mezcla de diversos flavivirus vivos atenuados y/o quiméricos vivos atenuados. Reivindicacion 25: La composicion de vacuna deshidratada de acuerdo con la reivindicacion 23, donde cada partícula o cada esfera contiene flavivirus vivos atenuados y/o quiméricos vivos atenuados de un unico tipo. Reivindicacion 26: Un método para preparar una vacuna, que comprende el paso de reconstituir la composicion segun se reivindica en una de las reivindicaciones 22 a 25 con una solucion acuosa.Claim 1: A stabilizer for vaccine compositions comprising one or more live attenuated flaviviruses, comprising, in an aqueous solution without proteins of animal origin and without added salts having: divalent cations; a buffer; 2.5% to 6.5% sorbitol; 2.5% to 13% sucrose; 0 to 7.5% trehalose and / or 0 to 7.5% of any other disaccharide or trisaccharide; 0.2% to 0.5% urea; 0.8% to 2.5% of an amino acid mixture comprising arginine (Arg), cystine (Cys-Cys), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine ( Met), phenylalanine (Phe), theonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), alanine (Ala), asparagine (Asn), aspartic acid (Asp), glutamic acid (Glu), glycine (Gly), proline (Pro) and serine (Ser). Claim 2: The stabilizer according to claim 1, comprising one or more buffers selected from the group consisting of TRIS (tris (hydroxymethyl) -aminomethane), acid HEPES (2- (4- (2-hydroxyethyl) -1- piperazinyl) ethanesulfonic) and potassium phosphate and / or sodium phosphate. Claim 6: A stabilized bulk aqueous vaccine composition comprising one or more live attenuated flaviviruses and the stabilizer as claimed in one or more of claims 1 to 5. Claim 15: A method for stabilizing one or more live attenuated flaviviruses, comprising the dilution of a purified and concentrated viral collection comprising one or more live flaviviruses attenuated by the stabilizer addition so as to obtain the final stabilizer concentrations defined in accordance with claims 1 to 5 in order to obtain a composition according to what is claimed in one or more of claims 6 to 14. Claim 22: A dehydrated vaccine composition that was obtained by drying the stabilized bulk composition as claimed in one or more of claims 6 to 14. Claim 23: The dehydrated vaccine composition according to claim 22, found present in the form of uniform particles or spheres. Claim 24: The dehydrated vaccine composition according to claim 23, wherein each particle or each sphere contains a mixture of various live attenuated flaviviruses and / or live attenuated chimerics. Claim 25: The dehydrated vaccine composition according to claim 23, wherein each particle or each sphere contains live attenuated flaviviruses and / or live attenuated chimerics of a single type. Claim 26: A method of preparing a vaccine, comprising the step of reconstituting the composition as claimed in one of claims 22 to 25 with an aqueous solution.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305390A EP2143440A1 (en) | 2008-07-09 | 2008-07-09 | Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072796A1 true AR072796A1 (en) | 2010-09-22 |
Family
ID=39942863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102524A AR072796A1 (en) | 2008-07-09 | 2009-07-06 | VACCINE STABILIZER AND COMPOSITION THAT INCLUDES ONE OR MORE FLAVIVIRUS LIVED OR CHEMERIC. STABILIZATION METHOD KIT |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8142795B2 (en) |
| EP (3) | EP2143440A1 (en) |
| JP (1) | JP5586598B2 (en) |
| KR (1) | KR101679723B1 (en) |
| CN (1) | CN102089002B (en) |
| AR (1) | AR072796A1 (en) |
| AU (1) | AU2009267401B2 (en) |
| BR (1) | BRPI0915813B1 (en) |
| CA (1) | CA2729758C (en) |
| DK (1) | DK2310048T3 (en) |
| ES (1) | ES2429130T3 (en) |
| IL (1) | IL210289A0 (en) |
| MX (1) | MX2011000312A (en) |
| MY (1) | MY150613A (en) |
| TW (1) | TWI460190B (en) |
| WO (1) | WO2010003670A1 (en) |
| ZA (1) | ZA201100107B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
| US9056070B2 (en) * | 2010-04-27 | 2015-06-16 | Universidad Manuela Beltran | Autologous biological cancer vaccine |
| FR2960781B1 (en) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | PREPARATION OF STABILIZED DRY ORAL VACCINE COMPOSED OF ATTENUATED LIVE VIRUS |
| BR112013005049A2 (en) | 2010-09-02 | 2016-05-31 | Sanofi Pasteur | stabilizer for the preparation of an injectable dry polio vaccine composition |
| LT2741740T (en) | 2011-08-12 | 2017-08-10 | Merial, Inc. | Vacuum-assisted preservation of biological products, in particular of vaccines |
| EP3246400B1 (en) | 2012-01-09 | 2019-10-23 | Sanofi Pasteur Biologics, LLC | Purification of herpes virus |
| EP3366301A1 (en) * | 2012-05-14 | 2018-08-29 | Teijin Limited | Radiation sterilization-resistant protein composition |
| WO2013177172A2 (en) * | 2012-05-21 | 2013-11-28 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| SG11201500412TA (en) | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions |
| CN104812408A (en) | 2012-07-24 | 2015-07-29 | 赛诺菲巴斯德有限公司 | vaccine composition for preventing dengue virus infection |
| US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| BR112015012515B1 (en) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| AR097762A1 (en) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | DRY FORMULATIONS OF VACCINES THAT ARE STABLE AT ENVIRONMENTAL TEMPERATURE |
| EP3057978B1 (en) | 2013-10-16 | 2022-09-14 | Merck Sharp & Dohme LLC | Method of microwave vacuum drying spherical-shaped pellets of biological materials |
| CA2927434C (en) * | 2013-10-16 | 2022-07-19 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| AR099470A1 (en) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | LIQUID CORRAL BIRD VIRUS VACCINES |
| TWI670085B (en) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | Swine virus vaccines that are liquid stable |
| NZ726315A (en) | 2014-05-14 | 2018-04-27 | Merial Inc | Methods for freeze-drying and rehydrating biologics |
| CN106999564A (en) | 2014-09-02 | 2017-08-01 | 赛诺菲巴斯德有限公司 | For the vaccine combination of dengue fever virus disease |
| US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
| CN106667944A (en) * | 2015-11-11 | 2017-05-17 | 北京泰德制药股份有限公司 | Sustained release preparation containing prostaglandin drugs |
| TWI766876B (en) | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | Compositions and methods for stabilizing flaviviruses with improved formulations |
| CN109952372A (en) * | 2016-09-16 | 2019-06-28 | 白血球保健股份有限公司 | Obtain the new method of the composition based on viral vectors effective for vaccine inoculation or gene therapy |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| KR102658198B1 (en) * | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | Stable virus-containing composition |
| WO2019048689A1 (en) | 2017-09-11 | 2019-03-14 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Tumor organoid model |
| JP7313345B2 (en) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | Composition for booster vaccination against dengue fever |
| CR20200212A (en) * | 2017-10-16 | 2020-07-17 | Serum Institute Of India Pvt Ltd | Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof |
| JOP20200140A1 (en) * | 2017-12-07 | 2022-10-30 | Merck Sharp & Dohme | Formulations of dengue virus vaccine compositions |
| CN108938574B (en) * | 2018-08-14 | 2020-10-16 | 江苏省农业科学院 | Freeze-dried heat-resistant protective agent for porcine pseudorabies live vaccine, and preparation method and application thereof |
| WO2020113197A1 (en) * | 2018-11-30 | 2020-06-04 | Vaccine Stabilization Institute | Viral formulations containing amino acids |
| KR102544928B1 (en) * | 2022-12-28 | 2023-06-20 | 주식회사 중앙백신연구소 | Composition for improving stability of antigen for animal vaccine or diagnosis comprising amino acid as effective component and uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3162019A (en) | 1962-11-16 | 1964-12-22 | Bethlehem Steel Corp | Method and apparatus for freezing liquids to be used in a freeze-drying process |
| GB1195363A (en) | 1966-06-17 | 1970-06-17 | Struthers Scientific Int Corp | Freeze Drying |
| US3313032A (en) | 1966-07-28 | 1967-04-11 | George J Malecki | Freeze-drying process and apparatus |
| US3655838A (en) | 1969-03-20 | 1972-04-11 | Organon | Method of pelletizing analytical or immunological reagents |
| DE2659546A1 (en) | 1976-12-30 | 1978-07-13 | Boehringer Mannheim Gmbh | METHOD FOR PRODUCING FROZEN GRANULES |
| US4211015A (en) | 1978-01-18 | 1980-07-08 | Baxter Travenol Laboratories, Inc. | Method and apparatus for making novel particulate compositions |
| FR2505657A1 (en) | 1981-05-13 | 1982-11-19 | Pasteur Institut | IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS |
| GB8802142D0 (en) | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
| ATE310824T1 (en) | 1991-09-19 | 2005-12-15 | CHIMERIC AND/OR GROWTH INHIBITED FLAVIVIRUSES | |
| US5307640A (en) | 1993-01-25 | 1994-05-03 | E. I. Du Pont De Nemours And Company | Apparatus and method for producing frozen particles of a liquid |
| US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| FR2742756B1 (en) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | STABILIZERS FOR LIVE VACCINES, VACCINES CONTAINING SAME, AND PROCESSES FOR THEIR PREPARATION |
| IL120202A (en) * | 1996-03-07 | 2001-03-19 | Akzo Nobel Nv | Container with freeze-dried vaccine components |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| HU228705B1 (en) | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
| BRPI9701774B8 (en) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | mutant and infectious yellow fever virus cdna, DNA construct, recombinant yellow fever virus and human vaccine against yellow fever infections. |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| US6528065B1 (en) | 1999-03-26 | 2003-03-04 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-3 virus vaccine |
| US6511667B1 (en) | 1999-03-26 | 2003-01-28 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-2 virus vaccine |
| JP2002540171A (en) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | Attenuated dengue type 4 virus vaccine |
| EP1165131A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-1 virus vaccine |
| AU3844101A (en) | 2000-02-16 | 2001-08-27 | Us Health | Avirulent, immunogenic flavivirus chimeras |
| ES2315221T3 (en) | 2000-05-30 | 2009-04-01 | Mahidol University | DAMAGED VIRUS VIRUSES AND THEIR USE IN A VACCINE COMPOSITION. |
| JP2004517699A (en) | 2001-01-30 | 2004-06-17 | ボード オブ リージェンツ ユニバーシティ オブ テキサス システム | Method for producing nanoparticles and microparticles by spray freezing into liquid |
| AT410634B (en) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | ATTENUATED LIFE VACCINE |
| GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| CA3114957C (en) | 2001-05-22 | 2022-02-08 | Stephen S. Whitehead | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| DE10124902A1 (en) | 2001-05-22 | 2002-11-28 | Bayer Ag | Particles of natural or synthetic surfactants, useful as emulsifier in aqueous systems, are prepared by cryo-gas spray method |
| CN1551782A (en) | 2001-06-01 | 2004-12-01 | ��������ķ������ | Chimeric flavivirus vectors |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| BR122018075730B1 (en) | 2002-01-15 | 2022-04-19 | Acambis, Inc | Flavivirus in the preparation of a vaccine composition and vaccine composition |
| EP1572941A4 (en) | 2002-02-26 | 2009-03-18 | Maxygen Inc | Novel flavivirus antigens |
| CA2849556A1 (en) * | 2002-04-11 | 2003-10-23 | Vu Truong-Le | Preservation of bioactive materials by freeze dried foam |
| US20030215455A1 (en) * | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| EP1575979B1 (en) | 2002-11-15 | 2009-12-23 | Sanofi Pasteur Biologics Co. | West nile virus vaccine |
| US20040213808A1 (en) * | 2002-12-11 | 2004-10-28 | Michael Lieberman | Recombinant vaccine against flavivirus infection |
| EP1794524B1 (en) | 2004-07-23 | 2012-01-18 | Bayer Technology Services GmbH | Sterile freezing, drying, storing, assaying and filling process (sfd-saf process) (pellet freeze-drying process for parenteral biopharmaceuticals) |
| WO2006134433A1 (en) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| AU2006257621B2 (en) | 2005-06-17 | 2011-08-11 | Centers For Disease Control And Prevention | Dengue serotype 2 attenuated strain |
| CA2616826A1 (en) * | 2005-08-04 | 2007-02-15 | Wyeth | Stabilizers for veterinary vaccines |
| CN101360821A (en) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | Stabilizing formulations for recombinant viruses |
| FR2903605A1 (en) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE |
| KR20090060453A (en) | 2006-09-25 | 2009-06-12 | 메디뮨 엘엘씨 | Stabilized antibody formulations and uses thereof |
| FR2906724B1 (en) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE. |
| RU2541784C2 (en) | 2006-11-07 | 2015-02-20 | Санофи Пастер Байолоджикс Ко. | Lyophilised composition for inducing immune response to flavivirus, composition and method for preparing it |
| FR2909286B1 (en) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE |
| SI2144998T1 (en) * | 2007-04-06 | 2017-05-31 | Takeda Vaccines, Inc. | Methods and compositions for live attenuated viruses |
-
2008
- 2008-07-09 EP EP08305390A patent/EP2143440A1/en not_active Withdrawn
-
2009
- 2009-07-06 AR ARP090102524A patent/AR072796A1/en not_active Application Discontinuation
- 2009-07-08 TW TW098123127A patent/TWI460190B/en active
- 2009-07-09 CN CN200980127083.8A patent/CN102089002B/en active Active
- 2009-07-09 US US12/500,156 patent/US8142795B2/en active Active
- 2009-07-09 BR BRPI0915813-8A patent/BRPI0915813B1/en active IP Right Grant
- 2009-07-09 WO PCT/EP2009/004980 patent/WO2010003670A1/en active Application Filing
- 2009-07-09 EP EP13183819.5A patent/EP2687229A1/en not_active Withdrawn
- 2009-07-09 DK DK09793888.0T patent/DK2310048T3/en active
- 2009-07-09 MY MYPI20105959 patent/MY150613A/en unknown
- 2009-07-09 JP JP2011517028A patent/JP5586598B2/en active Active
- 2009-07-09 EP EP09793888.0A patent/EP2310048B1/en active Active
- 2009-07-09 CA CA2729758A patent/CA2729758C/en active Active
- 2009-07-09 KR KR1020117000182A patent/KR101679723B1/en active IP Right Grant
- 2009-07-09 AU AU2009267401A patent/AU2009267401B2/en active Active
- 2009-07-09 ES ES09793888T patent/ES2429130T3/en active Active
- 2009-07-09 MX MX2011000312A patent/MX2011000312A/en active IP Right Grant
-
2010
- 2010-12-27 IL IL210289A patent/IL210289A0/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00107A patent/ZA201100107B/en unknown
-
2012
- 2012-03-26 US US13/429,542 patent/US20130028934A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2729758A1 (en) | 2010-01-14 |
| IL210289A0 (en) | 2011-03-31 |
| TWI460190B (en) | 2014-11-11 |
| EP2143440A1 (en) | 2010-01-13 |
| CN102089002A (en) | 2011-06-08 |
| AU2009267401B2 (en) | 2014-12-11 |
| CN102089002B (en) | 2014-12-10 |
| US20100015180A1 (en) | 2010-01-21 |
| TW201014868A (en) | 2010-04-16 |
| AU2009267401A1 (en) | 2010-01-14 |
| US20130028934A1 (en) | 2013-01-31 |
| KR101679723B1 (en) | 2016-11-25 |
| KR20110053325A (en) | 2011-05-20 |
| BRPI0915813A2 (en) | 2019-04-09 |
| MX2011000312A (en) | 2011-03-01 |
| ES2429130T3 (en) | 2013-11-13 |
| MY150613A (en) | 2014-01-30 |
| EP2310048A1 (en) | 2011-04-20 |
| CA2729758C (en) | 2017-03-07 |
| JP2011527300A (en) | 2011-10-27 |
| EP2687229A1 (en) | 2014-01-22 |
| JP5586598B2 (en) | 2014-09-10 |
| WO2010003670A1 (en) | 2010-01-14 |
| US8142795B2 (en) | 2012-03-27 |
| DK2310048T3 (en) | 2013-10-07 |
| ZA201100107B (en) | 2012-03-28 |
| EP2310048B1 (en) | 2013-09-11 |
| BRPI0915813B1 (en) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072796A1 (en) | VACCINE STABILIZER AND COMPOSITION THAT INCLUDES ONE OR MORE FLAVIVIRUS LIVED OR CHEMERIC. STABILIZATION METHOD KIT | |
| HRP20200871T1 (en) | Modified rsv f proteins and methods of their use | |
| ES2202425T3 (en) | DEHYDRATED COMPOSITION OF BLOOD FACTOR THAT INCLUDES TREHALOSA. | |
| AR108442A1 (en) | GDF15 FUSION PROTEINS AND USES OF THESE | |
| JP2019524771A5 (en) | ||
| BR112017027448A2 (en) | rsv vaccine | |
| AR078558A1 (en) | STABILIZING EXCIPIENT FOR AN INACTIVATED COMPLETE VIRUS VACCINE | |
| BR112014023869A2 (en) | loaded nutrient proteins and methods | |
| BR112015023168A8 (en) | crystalline diketopiperazine composition, methods of producing diketopiperiperine particles, producing a composition and treating and using a crystalline diketopiperazine composition | |
| PE20120358A1 (en) | FGF21 MUTANTS AND USES OF THEM | |
| RU2017106159A (en) | COMPOSITION OF FACTOR VIII | |
| AR080428A1 (en) | FORMULATIONS STABILIZED LIQUID CONTAINERS OF ANTIBODIES | |
| AR088460A1 (en) | FORMULATIONS OF ETANERCEPT STABILIZED WITH AMINO ACIDS | |
| RU2016118646A (en) | Stable aqueous MIA / CD-RAP protein compositions | |
| AR092796A1 (en) | VIRAL TYPE PARTICULATED COMPOSITION | |
| RU2015142981A (en) | RSV PROTEINS IN THE PREVIOUS CONFORMATION MERGER AND THEIR APPLICATION | |
| AR083034A1 (en) | STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH A WATERY FORMULATION WITH SODIUM CHLORIDE AT A WEAK ACID pH NEUTRAL | |
| BR112017008406A2 (en) | use of proline tolerant tripeptidyl peptidases in food additive compositions | |
| RU2009121566A (en) | VACCINE STABILIZATION BY LYOPHILIZATION | |
| EA201892446A1 (en) | PHARMACEUTICAL COMPOSITION | |
| AR056133A1 (en) | CANINE INFLUENZA VIRUSES AND RELATED COMPOSITIONS AND METHODS OF USE | |
| HRP20231581T1 (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
| EA201892493A1 (en) | Neurotoxin liquid formulation stabilized by tryptophane or tyrosine | |
| ES2052042T5 (en) | PROCEDURE FOR STABILIZATION OF VACCINES AND ASSOCIATIONS OF VACCINES OF ATTENATED VIRUSES PRESERVED IN LIOFILIZED FORM, AND COMPOSITIONS OBTAINED. | |
| EA202092926A2 (en) | LYOPHILIZED COMPOSITIONS CONTAINING FACTOR IX |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |